1

王元相

教授

研究领域：药物设计新理念、药物优化新策略、表观遗传创新药物研发

联系邮箱： wangyx95@mail.sysu.edu.cn

简介

王元相，教授，博士生导师。2012年毕业于中国科学院上海药物研究所，获得博士学位；之后五年分别在亚利桑那、犹他大学从事博士后研究工作。2017年经中山大学“百人计划二期”引进加入药学院开展独立工作。主要从事药物化学基础与应用基础研究，以肿瘤等重大临床需求为导向，瞄准与肿瘤发生发展及不良预后密切相关的表观遗传调控酶、转录因子、核受体等靶标，运用药物化学和化学生物学等手段，采取有针对性的策略开发药效高、成药性强的药物候选物，开展创新药物研究。近年来在J. Med. Chem.等期刊发表研究论文50余篇。申请国内外发明专利20项，获授权12项。主持国家自然科学基金、广东省自然科学基金、广州市重点研发计划等多项课题。

ORCID: https://orcid.org/0000-0001-5650-4396

 

招生招聘信息

1. 欢迎有志于创新药物研发的同学报考课题组2026级博士、硕士、工业药学研究生。

2. 课题组长期招聘具有药物化学、有机化学、化学生物学背景的博士后及研究员。

 

代表性论著

  1. Yi Zhang†, Qiongyu Shi†, Wei Fang†, Li Liu, Hong Yang, Xinqiao Liu, Yuting Huang, Ying Zhang, Xun Huang*, Yuanxiang Wang*. Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines. Journal of Medicinal Chemistry, 2025, 68, 10365-10383.
  2. Bang Li, Jin-Qi Yu, Zhenjiao Yang, Yuanxiang Wang*. PRMT5: A Promising Synthetical Lethal Target for MTAP-Deleted Cancer. Journal of Medicinal Chemistry, 2025, 68, 18143-18163.
  3. Wei Fang†, Jianwei Zheng†, Lin Deng, Yana An, Deqin Rong, Jianwei Wei, Xiao-Feng Xiong, Junjian Wang*, Yuanxiang Wang*. Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry, 2024, 67, 1481-1499.
  4. Jianwei Wei†, Qiongyu Shi†, Bang Li, Hong Yang, Li Liu, Ruilin Zhou, Zongbo Feng, Zhenjiao Yang, Jinhong Zhan, Xiao-Feng Xiong, Xun Huang*, Yuanxiang Wang*. Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2. Journal of Medicinal Chemistry, 2024, 67, 16056-16071.
  5. Chunju Yang†, Bang Li†, Zongbo Feng, Huaxuan Li, Hong Yang, Zhenjiao Yang, Li Liu, Qiongyu Shi, Hong Wang, Zhong-Zhu Chen, Xun Huang, Junjian Wang*, Yuanxiang Wang*. Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors. Journal of Medicinal Chemistry, 2024, 67, 16072-16087.
  6. Yi Zhang†, Hong Yang†, Bingbing Li†, Jiayi Li, Huaxuan Li, Qiongyu Shi, Bang Li, Zekun Wang, Jiahong Zheng, Ying Zhang, Hui Dong, Xun Huang*,Yuanxiang Wang*. Discovery of a New-Generation S‑Adenosylmethionine Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2. Journal of Medicinal Chemistry, 2023,66, 7629-7644.
  7. Zongbo Feng†, Chunju Yang†, Yi Zhang†, Huaxuan Li, Wei Fang, Junhua Wang, Yichu Nie, Chang-Yun Wang, Zhiqing Liu, Zhimin Jiang*, Junjian Wang*, Yuanxiang Wang*. Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP. Journal of Medicinal Chemistry, 2023, 66, 8086-8102.
  8. Jiahong Zheng, Bang Li, Yingqi Wu, Xiaoshuang Wu, Yuanxiang Wang*. Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies. Journal of Medicinal Chemistry, 2023, 66，8407-8427.
  9. Jianshan Mo†, Lin Deng†, Keren Peng†, Shumin Ouyang, Wen Ding, Linlin Lou, Ziyou Lin, Jianzheng Zhu, Jingwei Li, Qiyi Zhang, Pengyan Wang, Yuanzhen Wen, Xiaobing Chen, Peibin Yue, Jin-Jian Lu, Kai Zhu, Yongjiang Zheng*, Yuanxiang Wang*, Xiaolei Zhang*. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia. Journal of Hematology Oncology. 2023, 16(1), 15.
  10. Lin Deng†, Jianshan Mo†, Yi Zhang†, Keren Peng, Huaxuan Li, Shumin Ouyang, Zongbo Feng, Wei Fang, Jianwei Wei, Deqin Rong, Xiaolei Zhang*, Yuanxiang Wang*. Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3. Journal of Medicinal Chemistry, 2022, 65, 13094-13111.
  11. Deqin Rong†, Kaixin Zhou†, Wei Fang, Hong Yang, Yi Zhang, Qiongyu Shi, Yuting Huang, Jiayi Li, Hui Dong, Lanlan Li, Jian Ding*, Xun Huang*, Yuanxiang Wang*. Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5. Journal of Medicinal Chemistry, 2022, 65, 7854-7875.
  12. Huaxuan Li†, Shumin Ouyang†, Yi Zhang, Keren Peng, Wei Fang, Zhiqing Liu*, Chang-Yun Wang*, Xiaolei Zhang*, Yuanxiang Wang*. Structural optimization of Imidazo[1, 2-a]pyridine derivatives for the treatment of gastric cancer via STAT3 signaling pathway. European Journal of Medicinal Chemistry, 2022, 244, 114858.
  13. Shumin Ouyang†, Huaxuan Li†, Linlin Lou, Qiuyao Huang, Zhenhua Zhang, Jianshan Mo, Min Li, Jiaye Lu, Kai Zhu, Yunjie Chu, Wen Ding, Jianzheng Zhu, Ziyou Lin, Lin Zhong, Junjian Wang, Peibin Yue, James Turkson, Peiqing Liu*, Yuanxiang Wang*, Xiaolei Zhang*, Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer.Redox biology, 2022, 52, 102317.
  14. Yan Zhong†, Lin Deng†, Shuo Shi†, Qiu-yao Huang, Shu-min Ou-Yang, Jian-shan Mo, Kai Zhu, Xin-ming Qu, Peiqing Liu*, Yuanxiang Wang*, Xiaolei Zhang*.The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts. Acta Pharmacol Sin. 2022, 43, 1013-1023.

  15. Yi Zhang, Deqin Rong, Bingbing Li,Yuanxiang Wang*. Targeting epigenetic regulators with covalent small-molecule inhibitors. Journal of Medicinal Chemistry. 2021, 64, 7900-7925.

  16. Qiuyao Huang†, Yan Zhong†, Bingbing Li†, Shumin Ouyang, Lin Deng, Jianshan Mo, Shuo Shi, Nan Lv, Ruibo Wu, Peiqing Liu, Wenhao Hu, Xiaolei Zhang*, Yuanxiang Wang*, Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).European Journal of Medicinal Chemistry, 2021, 221, 113525.

  17. Qiyao Zheng†, Hui Dong†, Jianshan Mo†, Yi Zhang, Jie Huang, Shumin Ouyang, Shuo Shi, Kai Zhu, Xinmin Qu, Wenhao Hu, Peiqing Liu*, Yuanxiang Wang*, Xiaolei Zhang*. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics, 2021, 11, 824-840.

  18. Qiuyao Huang†, Yan Zhong†, Hui Dong, Qiyao Zheng, Shuo Shi, Kai Zhu, Xinming Qu, Wenhao Hu, Xiaolei Zhang*, Yuanxiang Wang*. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? European Journal of Medicinal Chemistry, 2020, 187, 111922.

  19. Qiuyao Huang†, Hui Dong†, Bingbing Li, Wenhao Hu, Yuanxiang Wang*. Rhodium catalyzed direct C3-ethoxycarbonylmethylation of imidazo[1,2-a]pyridines with ethyl diazoacetate. Tetrahedron, 2020, 76, 130998.

  20. Bingbing Li, Deqin Rong, Yuanxiang Wang*. Targeting protein-protein interaction with covalent small-molecule Inhibitors. Current Topics in Medicinal Chemistry, 2019, 19, 1872-1876.

  21. Yuanxiang Wang*, Wenhao Hu, Yanqiu Yuan*. Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery. Journal of Medicinal Chemistry. 2018, 61, 9429-9441.

  22. Yuanxiang Wang†, Yanmei Hu†, Shuting Xu, Yongtao Zhang, Rami Musharrafieh, Raymond Kin Hau, Chunlong Ma, and Jun Wang*. In vitro pharmacokinetic optimizations of AM2-S31N channel blockers led to the discovery of slow-binding inhibitors with potent antiviral activity against drug-resistant influenza A viruses. Journal of Medicinal Chemistry. 2018, 61, 1074-1085.